Search
Close this search box.

Kimiara company advisory board

Scientific meeting (advisory board) of Kimiara company regarding the position of Lepronzo (eplerenone 25 and 50) in the treatment of heart failure and hypertension on 10 September 2022 with the presence of experts of the Iranian Cardiology and Nephrology society, including:

  • Dr. Ghasemi (President of Iranian Atherosclerosis Association)
  • Dr. Sezavar
  • Dr. Navid
  • Dr. Riahi
  • Dr. Sharif Kashani
  • Dr. Organi
  • Dr. Haj Ahmadi
  • Dr. Naderi
  • Dr. Tagvi

and Dr. Mahmoudi.

Kimiara company advisory board Kimiara company advisory board Kimiara company advisory board

In this meeting, the main position of Lepronzo (eplerenone) in the treatment of heart failure, which is class one, and its indication in hypertension were evaluated.

The physicians believed that mineralocorticoid antagonists are in the first line of the treatment along with other drugs in the heart failure and have impressive effect on the progress of heart failure.

Similar news ...

Shahid Madani Tabriz Heart Center morning meeting

Shahid Madani Tabriz Heart Center morning meeting was held on july 23, 1400 on the role of Ticagrelor. in the treatment of Acute Coronary Syndrome and presentation of clinical studies. This meeting was held in the presence of respected professors, including: Interventionist: Dr.Separham, Dr.Ghaffari Dr.Aslan Abadi Dr.Sohrabi Electrophysiologist: Dr.Abbas Nezhad

Read more...

Scientific program of Tehran Heart Center Cath Conference

Holding the scientific program of Tehran Heart Center Cath Conference with lecture of Dr. Rahimi, (Kimiara Company’ Medical Science Liaison), on the role of Ticagloror molecule in the treatment of Acute Coronary Syndrome and review of clinical studies on Thursday, July 24, 1400. In this scientific meeting: The superior properties

Read more...